Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2018 · 85,727 citations
2Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung CancerOriginal Research · 2019 · 1,061 citations
3Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> MutationsLate-Phase Clinical Trial · 2013 · 3,227 citations
4Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2Original Research · 2001 · 11,647 citations
5Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerOriginal Research · 2011 · 2,563 citations
6Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIARetrospective Study · 2014 · 396 citations
7HER2 <sup>YVMA</sup> drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapyOriginal Research · 2009 · 186 citations
8Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272Original Research · 2006 · 135 citations
9Image-Based Consensus Molecular Subtyping Refines Prognostication in Stage II/III Colorectal Cancer: A Retrospective Analysis of the SCOT TrialJournal of Clinical Oncology · 2026
10Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister StudyJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology

More from Peking University